TASLY(SH:600535) Zhong Guo Jin Rong Xin Xi Wang·2025-12-31 11:27Core Insights - The "Liver Future Summit Dialogue" series, initiated in 2025, aims to enhance the diagnosis and treatment of fatty liver disease in the northwest region of China, with significant participation and collaboration among various healthcare institutions [1][3] - The initiative addresses the rising prevalence of fatty liver disease, particularly among younger populations, and aims to establish a multi-disciplinary approach to improve healthcare delivery in underserved areas [3] Group 1: Event Overview - The series has successfully conducted 9 academic exchange and free clinic events, attracting a total of 3,800 participants [1] - The events are supported by the Chinese Medical Doctor Association and involve partnerships with local hospitals to enhance healthcare capabilities through resource sharing and collaborative efforts [1][3] Group 2: Health Challenges and Solutions - Fatty liver disease has become a significant public health issue in China, particularly in the northwest, where dietary habits and healthcare resource distribution contribute to its rising incidence [3] - The initiative aims to create a "provincial-city-county" fatty liver prevention alliance, promoting a replicable chronic disease management model to improve local healthcare standards [3] Group 3: Corporate Social Responsibility - Tianshili Pharmaceutical Group emphasizes social responsibility and health care as core values, launching various health initiatives in 2025, including projects focused on stroke and cardiovascular disease prevention [4] - The company plans to continue its commitment to health promotion with new projects aimed at resource integration and innovative healthcare models in 2026 [4]